Structure (77f4fa2d 8c1c 4906 880f B6c1c10f2655 01)
Mirabegron Tablet, Extended Release
Product Images NDC 70518-4304
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Mirabegron (NDC 70518-4304). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure 1 (77f4fa2d 8c1c 4906 880f B6c1c10f2655 02)
Figure 2 (77f4fa2d 8c1c 4906 880f B6c1c10f2655 03)
This text appears to contain information about various drugs and their dosages as substrates for CYP3A4 and CYP2D6 enzymes. The text also mentions recommendations for dose adjustments based on PK fold change and provides examples of some drugs' single doses. It outlines potential interactions and includes suggestions for starting dose adjustments for certain medications. The text seems to emphasize the importance of understanding how these drugs may affect each other's metabolism when taken together.*
Figure 3 (77f4fa2d 8c1c 4906 880f B6c1c10f2655 04)
Figure 4 (77f4fa2d 8c1c 4906 880f B6c1c10f2655 05)
This is a data sheet showing numerical values at regular intervals. It includes different values from 0 to -2.25 and also mentions a mean change from baseline value of -2.00. The data seems to be related to comparing placebo and a medication named mirabegron at a dosage of 50 mg. It involves a study with a sample size of 480 for placebo and 473 for mirabegron.*
Figure 5 (77f4fa2d 8c1c 4906 880f B6c1c10f2655 06)
This data shows the mean change from baseline for different time points on a study involving mirabegron 50 mg and a placebo. The values range from 0.00 to -2.00 with increments of -0.25. The study involves a total of 325 participants for the placebo group and 312 participants for the mirabegron 50 mg group at 12 weeks.*
Figure 6 (77f4fa2d 8c1c 4906 880f B6c1c10f2655 07)
Figure 7 (77f4fa2d 8c1c 4906 880f B6c1c10f2655 08)
This text appears to show a table or chart displaying the mean change from baseline for different values, such as -0.25, -0.50, -0.75, etc., with corresponding data points. The table also mentions the number of cases (n=257) and indicates the comparison between mirabegron doses (25 mg vs. 50 mg) at different weeks.*
Figure 8 (77f4fa2d 8c1c 4906 880f B6c1c10f2655 09)
This text appears to describe a table or data related to a study comparing the mean change from baseline in a group of patients taking different doses of mirabegron and placebo over a certain period of time. The table includes values such as -2.00, -2.25, and BL 4 8 12 Week, indicating the timeframe of the study and the dosage groups being compared. The data suggests that mirabegron was administered at 25mg and 50mg doses, with 410 and 426 participants respectively, along with a placebo group with 415 participants.*
Mm1 (Mirabegron 50mg 70518 4304 00)
The text provides information about Mirabegron Extended-Release 50mg Tablets, with a quantity of 90 tablets. It includes the prescription-only status, NDC numbers, expiration date, manufacturer details (Zydus Pharmaceuticals from Pennington, NJ), and a warning not to cut, crush, or chew the tablet. The text also mentions directions for use, storage conditions, and repackaging details.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
